28 June 2019 - Document open to public comment until 19 July 2019
The Institute for Clinical and Economic Review has posted a draft scoping document outlining a planned review of the comparative clinical effectiveness and value treatments for acute migraine, including: two oral CGRP receptor antagonists, rimegepant (Biohaven) and ubrogepant (Allergan); and a 5-HT1f agonist lasmiditan (Eli Lilly).
All three of these agents are under FDA review with an anticipated decision in the final quarter of 2019.